Cargando…
Mitochondria as a Target for Mitigating Sarcopenia
Sarcopenia is the loss of muscle mass, strength, and physical function that is characteristic of aging. The progression of sarcopenia is gradual but may be accelerated by periods of muscle loss during physical inactivity secondary to illness or injury. The loss of mobility and independence and incre...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335344/ https://www.ncbi.nlm.nih.gov/pubmed/30687111 http://dx.doi.org/10.3389/fphys.2018.01883 |
_version_ | 1783387866958659584 |
---|---|
author | Coen, Paul M. Musci, Robert V. Hinkley, J. Matthew Miller, Benjamin F. |
author_facet | Coen, Paul M. Musci, Robert V. Hinkley, J. Matthew Miller, Benjamin F. |
author_sort | Coen, Paul M. |
collection | PubMed |
description | Sarcopenia is the loss of muscle mass, strength, and physical function that is characteristic of aging. The progression of sarcopenia is gradual but may be accelerated by periods of muscle loss during physical inactivity secondary to illness or injury. The loss of mobility and independence and increased comorbidities associated with sarcopenia represent a major healthcare challenge for older adults. Mitochondrial dysfunction and impaired proteostatic mechanisms are important contributors to the complex etiology of sarcopenia. As such, interventions that target improving mitochondrial function and proteostatic maintenance could mitigate or treat sarcopenia. Exercise is currently the only effective option to treat sarcopenia and does so, in part, by improving mitochondrial energetics and protein turnover. Exercise interventions also serve as a discovery tool to identify molecular targets for development of alternative therapies to treat sarcopenia. In summary, we review the evidence linking mitochondria and proteostatic maintenance to sarcopenia and discuss the therapeutic potential of interventions addressing these two factors to mitigate sarcopenia. |
format | Online Article Text |
id | pubmed-6335344 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63353442019-01-25 Mitochondria as a Target for Mitigating Sarcopenia Coen, Paul M. Musci, Robert V. Hinkley, J. Matthew Miller, Benjamin F. Front Physiol Physiology Sarcopenia is the loss of muscle mass, strength, and physical function that is characteristic of aging. The progression of sarcopenia is gradual but may be accelerated by periods of muscle loss during physical inactivity secondary to illness or injury. The loss of mobility and independence and increased comorbidities associated with sarcopenia represent a major healthcare challenge for older adults. Mitochondrial dysfunction and impaired proteostatic mechanisms are important contributors to the complex etiology of sarcopenia. As such, interventions that target improving mitochondrial function and proteostatic maintenance could mitigate or treat sarcopenia. Exercise is currently the only effective option to treat sarcopenia and does so, in part, by improving mitochondrial energetics and protein turnover. Exercise interventions also serve as a discovery tool to identify molecular targets for development of alternative therapies to treat sarcopenia. In summary, we review the evidence linking mitochondria and proteostatic maintenance to sarcopenia and discuss the therapeutic potential of interventions addressing these two factors to mitigate sarcopenia. Frontiers Media S.A. 2019-01-10 /pmc/articles/PMC6335344/ /pubmed/30687111 http://dx.doi.org/10.3389/fphys.2018.01883 Text en Copyright © 2019 Coen, Musci, Hinkley and Miller. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Physiology Coen, Paul M. Musci, Robert V. Hinkley, J. Matthew Miller, Benjamin F. Mitochondria as a Target for Mitigating Sarcopenia |
title | Mitochondria as a Target for Mitigating Sarcopenia |
title_full | Mitochondria as a Target for Mitigating Sarcopenia |
title_fullStr | Mitochondria as a Target for Mitigating Sarcopenia |
title_full_unstemmed | Mitochondria as a Target for Mitigating Sarcopenia |
title_short | Mitochondria as a Target for Mitigating Sarcopenia |
title_sort | mitochondria as a target for mitigating sarcopenia |
topic | Physiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335344/ https://www.ncbi.nlm.nih.gov/pubmed/30687111 http://dx.doi.org/10.3389/fphys.2018.01883 |
work_keys_str_mv | AT coenpaulm mitochondriaasatargetformitigatingsarcopenia AT muscirobertv mitochondriaasatargetformitigatingsarcopenia AT hinkleyjmatthew mitochondriaasatargetformitigatingsarcopenia AT millerbenjaminf mitochondriaasatargetformitigatingsarcopenia |